Open Access Repository

Myocilin predictive genetic testing for primary open-angle glaucoma leads to early identification of at-risk individuals

Souzeau, E, Tram, KH, Witney, M, Ruddle, JB, Graham, SL, Healey, PR, Goldberg, I, Mackey, DA, Hewitt, AW ORCID: 0000-0002-5123-5999, Burdon, KP ORCID: 0000-0001-8217-1249 and Craig, JE 2017 , 'Myocilin predictive genetic testing for primary open-angle glaucoma leads to early identification of at-risk individuals' , Ophthalmology, vol. 124, no. 3 , pp. 303-309 , doi: 10.1016/j.ophtha.2016.11.011.

Full text not available from this repository.

Abstract

Purpose: To assess the difference in severity of disease in primary open-angle glaucoma (POAG) patients with a Myocilin (MYOC) disease-causing variant who presented through normal clinical pathways (Clinical cases) versus those who were examined following genetic testing (Genetic cases).Design: Retrospective clinical and molecular study.Participants: Seventy-three MYOC mutation carriers identified through the Australian and New Zealand Registry of Advanced Glaucoma.Methods: Individuals were classified based on how they first presented to an ophthalmologist: Clinical cases were referred by their general practitioner or optometrist, and Genetic cases were referred following positive results from genetic testing for the previously identified familial MYOC variant (cascade genetic testing). All cases were then sub-classified into 4 groups (unaffected, glaucoma suspect, glaucoma, advanced glaucoma) according to the severity of disease at the time of their first examination by an ophthalmologist.Main Outcome Measures: Glaucoma clinical parameters and age at presentation.Results: At their first examination, 83% of Genetic cases were unaffected and 17% were glaucoma suspect, whereas among Clinical cases 44% were glaucoma suspect, 28% had glaucoma, and 28% had advanced glaucoma. Genetic cases were significantly younger at presentation than Clinical cases (40.6 ± 12.5 vs. 47.5 ± 16.7 years; P = 0.018). The mean highest intraocular pressure (32.2 ± 9.7 vs. 17.6±  3.6 mmHg; P P = 0.006), and mean deviation on visual field testing (-10.0 ± 10.3 vs. -1.2 ± 1.2; P MYOC p.Gln368Ter variant were further analyzed separately to account for the phenotypic variability of different disease-causing variants. All findings remained significant after adjusting for the common MYOC p.Gln368Ter variant.Conclusions: Our findings demonstrated that MYOC cascade genetic testing for POAG allows identification of at-risk individuals at an early stage or even before signs of glaucoma are present. To our knowledge, this is the first study to demonstrate the clinical utility of predictive genetic testing for MYOC glaucoma.

Item Type: Article
Authors/Creators:Souzeau, E and Tram, KH and Witney, M and Ruddle, JB and Graham, SL and Healey, PR and Goldberg, I and Mackey, DA and Hewitt, AW and Burdon, KP and Craig, JE
Keywords: glaucoma, genetic testing
Journal or Publication Title: Ophthalmology
Publisher: Elsevier Science Inc
ISSN: 0161-6420
DOI / ID Number: 10.1016/j.ophtha.2016.11.011
Copyright Information:

Copyright 2016 American Academy of Opthalmology

Related URLs:
Item Statistics: View statistics for this item

Actions (login required)

Item Control Page Item Control Page
TOP